Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort
European Journal of Neurology · 2024
DOI: 10.1111/ene.16399 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Yusuf A Rajabally und 3 weiteren Autor:innen. Beteiligte Einrichtung: Aston Medical School, Aston University, Birmingham, UK. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and purpose The amplitude, timing, and determinants of improvement with available treatments are uncertain in chronic inflammatory demyelinating polyneuropathy (CIDP). Our primary objective was to quantify categorized outcomes with routine care.
Methods
We retrospectively studied treatment response within 36 months from initiation in 112 consecutive subjects with CIDP. Response was classified into a proposed new "CIDP treatment‐response category" (CT‐RC), based on achieved endpoints. Determinants of the CT‐RC, of timing of maximum improvement, and of treatment discontinuation were ascertained.
Results
The CT‐RC demonstrated high concurrent validity with current outcome measures. Thirty‐six subjects (32.1%) achieved a “complete response,” 37 (33%) a “good partial response,” 10 (8.9%) a “moderate partial response,” and 15 (13.4%) a “poor partial response.” Fourteen subjects (12.5%) were “nonresponsive.” The CT‐RC was independently predicted only by age. Mean time to maximum improvement was 12.1 months (range = 1–36) and was not associated with any pretreatment covariate. Treatment discontinuation occurred in 24 of 62 (38.2%) partial responders and was only associated with shorter pretreatment disease duration. Nonresponders were older and received a similar number of treatments compared to responders.
Conclusions
CT‐RC classification indicates persistent disability in >60% of treatment responders in CIDP. Timing of maximum improvement is variable, frequently delayed, and unpredictable. Treatment withdrawal without deterioration is achievable in approximately 40% of subjects and may be more likely with prompt treatment. Treatment withdrawal in partial responders and limited escalation in nonresponders suggest implication of physician‐ and patient‐related factors in suboptimal response. More effective treatments/treatment methods and better understanding of other factors influencing response are needed in CIDP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aston Medical School, Aston University, Birmingham, UK.
- Department of Neurology, Inflammatory Neuropathy Clinic, University Hospitals Birmingham, Birmingham, UK.
- Department of Translational Medicine, Seoul National University College of Medicine, Seoul, South-Korea.
ORCID-Profile: Yusuf A Rajabally, Young Gi Min, Christina Englezou
Zitieren
APA
Rajabally, Y. A., Min, Y. G., Nazeer, K. K., & Englezou, C. (2024). Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort. European Journal of Neurology. https://doi.org/10.1111/ene.16399
Vancouver
Rajabally YA, Min YG, Nazeer KK, Englezou C. Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort. European Journal of Neurology. 2024. doi:10.1111/ene.16399
BibTeX
@article{Rajabally2024,
author = {Rajabally, Yusuf A and Min, Young Gi and Nazeer, Kabir K and Englezou, Christina},
title = {Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16399}
}
EUVIMED